. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: J Viral Hepat. 2014 Nov 24;22(8):675–681. doi: 10.1111/jvh.12368

Table 1.

Patient characteristics stratified by alternate therapy group (TDF monotherapy or ETV+TDF combination therapy) in patients with a partial virological response to ETV

	TDF monotherapy (n = 25)	ETV and TDF (n = 43)	p-value
Median age (years)	40 (19 - 75)	40 (26 - 69)	0.42
Male	64%	63%	0.92
HBeAg positive	88%	95%	0.26
Naïve HBV DNA (log₁₀ IU/mL)	7.74 ± 1.17	7.97 ± 0.90	0.43
Median time on ETV before switch (months)	21 (12 - 59)	25 (14 - 47)	0.71
Median time on alternate therapy (months)	16 (6 - 56)	17 (6 - 72)	0.53
Pre-ETV monotherapy
HBV DNA (log₁₀ IU/mL)	6.69 ± 2.03	7.71 ± 1.15	0.01
Median ALT (IU/L)	47 (8 - 153)	51 (17 - 156)	0.33
At Switch
HBV DNA (log₁₀ IU/mL)	3.10 ± 0.95	3.57 ± 0.90	0.05
Median ALT (IU/L)	29 (12 - 61)	26 (9 - 75)	0.41

TDF, tenofovir; ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase